<DOC>
	<DOCNO>NCT02306772</DOCNO>
	<brief_summary>This Phase I , open-label , single-site trial evaluate drug release , use Scintigraphic image mesalazine plasma level ( PK ) healthy subject . Overall , nine [ 9 ] subject per prototype coating ( total 18 ) evaluate . Eligible subject assign 1:1 ratio receive radio-labelled TP05 ; first 9 subject receive formulation B second 9 subject receive formulation A . The subject treat radio-labelled study medication .</brief_summary>
	<brief_title>TP0501 - Pharmaco-Scintigraphic-Study</brief_title>
	<detailed_description />
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . Healthy subject , male nonpregnant , nonlactating female , 18 55 year old . Females child bear potential must negative serum pregnancy test prior intake study drug , must use hormonal ( oral , implantable injectable ) double barrier method birth control throughout study . Females unable bear child must documentation source record ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . 2 . Ability subject participate fully aspects clinical trial . 3 . Voluntarily sign informed consent must obtain document . 1 . Participating clinical study involve investigational drug dosage form within previous 2 month . 2 . History alcohol drug abuse . 3 . Radiation exposure clinical trial , include present study diagnostic Xray exclude background radiation , exceed 5 mSV last 12 month 10 mSv last 5 year . No subject whose occupational exposure monitor participate study . 4 . Any nuclear medicine procedure prior study day 1 might interfere scintigraphic image acquire . 5 . Clinically significant abnormal biochemistry , haematology urine analysis : White blood count &lt; 3 x 109/L &gt; 8 x 109/L Lymphocyte count &lt; 0.85 x 109/L Haemoglobin &lt; 110 g/L Platelet count &lt; 125 x 109/L &gt; 600 x 109/L AlanineAminotransferase ( ALT ) AspartateAminotransferase ( AST ) &gt; 2x upper limit normal Alkaline Phosphatase &gt; 2x upper limit normal Serum Creatinine &gt; upper limit normal 6 . History gastrointestinal surgery , exception appendectomy unless perform within previous 12 month . 7 . History cardiovascular , renal , hepatic , respiratory particularly gastrointestinal disease , especially peptic ulceration , gastrointestinal bleeding , ulcerative colitis , Crohn ` disease Irritable Bowel Syndrome ( within previous 12 month ) . 8 . History adverse reaction allergy Mesalazine salicylates . 9 . Acute diarrhoea constipation 14 day predict first study day . If screening occurs &gt; 14 day first study day , criterion determine first study day . Diarrhoea define passage liquid faeces and/or qa stool frequency &gt; 3 time per day . Constipation define failure open bowel frequently every day . 10 . Donation blood within previous three month . 11 . Positive HBVAntigen ( HepatitisB ) , HCVAntibody ( HepatitisC ) HIVAntibody ( Human Immunodeficiency Virus ) result . 12 . Overthecounter ( OTC ) prescription medication ( include laxative , vitaminpills natural herbal remedy ) screen visit ( visit 1 ) completion study . Occasional paracetamol acetylsalicylacid permit . 13 . Failure satisfy Principle Investigator participate reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>